Waiting
Traitement de la connexion…

Trial ends in Request Full Access Tell Your Colleague About Jove
Journal / Medicine / Tumor Treating Field Therapy in Combination with…
JoVE Journal
Medicine

Ce contenu est en libre accès.

JoVE Journal Medicine
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
 

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Article DOI: 10.3791/51638-v • 06:15 min • October 27th, 2014
October 27th, 2014 •
1
1Southern Illinois University School of Medicine

Chapitres

résumé
Automatic Translation

A novel methodology that is employed for the treatment of recurrent glioblastomas is described. This treatment approach employs the application of alternating electric tumor treating fields (TTFields), known as TTF Therapy in combination with bevacizumab, a targeted agent that is currently FDA approved as monotherapy.

Tags

Tumor Treating Field Therapy Bevacizumab Recurrent Glioblastoma TTF Therapy FDA Approval Alternating Electric Fields Tumor Cell Kill Glioma Incidence Resistance To Treatment Bevacizumab Efficacy VEGF Pathway Radiographic Response Progression-free Survival Corticosteroid Requirements Overall Survival Quality Of Life Novel Approaches
Read Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter